Current directions in the treatment of classical Hodgkin lymphoma by Frank G. Keller, Brad Kahl, Jonathan W. Friedberg

Get full text

Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis by Steve Kanters, Graeme Ball, Brad Kahl, Adriana Wiesinger, Eve H. Limbrick-Oldfield, Akshay Sudhindra, Julia Thornton Snider, Anik R. Patel

Get full text

Overcoming barriers to drug development and enrollment in clinical trials for adolescents and young adults with lymphoma by Keri Toner, Carl E. Allen, Shweta Jain, Brad Kahl, John Leonard, Heather Wasserstrom, Jonathan W. Friedberg, Nita L. Seibel, Kara Kelly

Get full text

Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis by Simon Rule, Martin Dreyling, Andre Goy, Georg Hess, Rebecca Auer, Brad Kahl, José-Ángel Hernández-Rivas, Keqin Qi, Sanjay Deshpande, Lori Parisi, Michael Wang

Get full text

T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECO... by Catherine Diefenbach, Opeyemi Jegede, Richard Ambinder, Jonathon Cohen, Michael Robertson, Kevin David, Ranjana Advani, Timothy Fenske, Stefan Barta, Neil Palmisiano, Jakub Svoboda, David Morgan, Reem Karmali, Brad Kahl, Stephen M. Ansell

Get full text

P631: CHARACTERIZATION OF ZANUBRUTINIB SAFETY/TOLERABILITY PROFILE AND COMPARISON WITH IBRUTINIB PROFILE IN PATIENTS WITH B-CELL MALIGNANCIES: POST HOC ANALYSIS OF A LARGE CLINICAL... by Jennifer R. Brown, Barbara Eichhorst, Paolo Ghia, Wojciech Jurczak, Brad Kahl, Nicole Lamanna, Tadeusz Robak, Mazyar Shadman, Constantine Tam, Lugui Qiu, Aileen Cohen, Meng Zhang, Tommi Salmi, Jason Paik, Liping Wang, Jun Zhang, Han MA, Alessandra Tedeschi

Get full text

P1182: A PROSPECTIVE STUDY OF TCR MEASURABLE RESIDUAL DISEASE IN PERIPHERAL T-CELL LYMPHOMA by Austin Jacobsen, Ying Huang, Natalie Hill, Karina Elias, Matthew Holman, Skyler Gordon, Nicole Foley, David Russler-Germain, Marcus Watkins, Eric D. Jacobsen, Alison Moskowitz, Amanda Cashen, Todd A. Fehniger, Brad Kahl, Armin Ghobadi, Beth Reagan, Anne Fischer, Fei Wan, Steven Horwitz, Neha Mehta-Shah

Get full text

A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma by Todd A. Fehniger, Marcus P. Watkins, Nkiruka Ezenwajiaku, Fei Wan, David D. Hurd, Amanda F. Cashen, Kristie A. Blum, Andre Goy, Timothy S. Fenske, Nina D. Wagner-Johnston, Kenneth Carson, Marilyn J. Siegel, David Russler-Germain, Stephanie E. Schneider, Neha Mehta-Shah, Brad Kahl, Nancy L. Bartlett

Get full text

Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab by Amy K. Erbe, Wei Wang, Lakeesha Carmichael, Anna Hoefges, Bartosz Grzywacz, Patrick K. Reville, Erik A. Ranheim, Jacquelyn A. Hank, KyungMann Kim, Songwon Seo, Eneida A. Mendonca, Yiqiang Song, Vaishalee P. Kenkre, Fangxin Hong, Randy D. Gascoyne, Elisabeth Paietta, Sandra J. Horning, Jeffrey S. Miller, Brad Kahl, Paul M. Sondel

Get full text

HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy by Amy K. Erbe, Wei Wang, Patrick K. Reville, Lakeesha Carmichael, KyungMann Kim, Eneida A. Mendonca, Yiqiang Song, Jacquelyn A. Hank, Wendy B. London, Arlene Naranjo, Fangxin Hong, Michael D. Hogarty, John M. Maris, Julie R. Park, Julie R. Park, M. F. Ozkaynak, Jeffrey S. Miller, Andrew L. Gilman, Brad Kahl, Alice L. Yu, Alice L. Yu, Paul M. Sondel, Paul M. Sondel

Get full text

P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW... by Talha Munir, Mazyar Shadman, Tadeusz Robak, Jennifer R. Brown, Brad Kahl, Paolo Ghia, Krzysztof Giannopoulos, Martin Simkovic, Anders Österberg, Luca Laurenti, Patricia Walker, Stephen Opat, Hanna Ciepluch, Richard Greil, Merit Hanna, Monica Tani, Marek Trneny, Danielle M. Brander, Ian W. Flinn, Sebastian Grosicki, Emma Verner, Alessandra Tedeschi, Sophie De Guibert, Gayane Tumyan, Kamel Laribi, Jose Antonio Garcia Marco, Jianyong LI, Tian Tian, Vanitha Ramakrishnan, Yu Liu, Andy Szeto, Jason Paik, Aileen Cohen, Constantine Tam, Wojciech Jurczak

Get full text

Identification of genetic subtypes in follicular lymphoma by Victoria Shelton, Rajesh Detroja, Ting Liu, Keren Isaev, Anjali Silva, Verena Passerini, Mehran Bakhtiari, Lourdes Calvente, Michael Hong, Michael Y. He, Saloni Modi, Samantha A. Hershenfeld, Maja Ludvigsen, Charlotte Madsen, Stephen Hamilton-Dutoit, Francesco Annibale d’Amore, Marianne Brodtkorb, Nathalie A. Johnson, Tara Baetz, David LeBrun, Josh W. D. Tobin, Maher K. Gandhi, Andrew J. Mungall, Wei Xu, Susana Ben-Neriah, Christian Steidl, Jan Delabie, Rosemarie Tremblay-LeMay, Opeyemi Jegede, Oliver Weigert, Brad Kahl, Andrew M. Evens, Robert Kridel

Get full text

Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers by Viktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, Kaitlin Annunzio, Aditi Saha, Ning Dong, David Qualls, Behzad Amoozgar, Brad Kahl, John Baird, Pavan Challa, Scott F Huntington, Jennifer Santos, Steven Bair, Mayur Narkhede, Shuning Li, Zachary Frosch, Carrie Ho, Stephen D Smith, Allison Winter, Daniel Landsburg, Fateeha Furqan, Mehdi Hamadani, Katelin Baird, Jason Romancik, Hanan Alharthy, Jennie Law, Leyla Bojanini, Ranjana Advani, Boyu Hu, Patrick Connor Johnson, Natalie S. Grover, Mwanasha Merril, Jennifer L. Crombie, Nazila Shafagati, Cole Sterling, Loretta J. Nastoupil, Narendranath Epperla, Emily C Ayers

Get full text